Surgery Partners stitches a steady course: Q2 2026 results reaffirm revenue forecast as debt looms and Idaho Falls waits
Ticker: NASDAQ: SGRY • EPS coverage not disclosed in the release • revenue forecast reaffirmed • earnings surprise not evident in quarterly numbers • EPS consensus considerations looming
Executive snapshot
Surgery Partners, Inc. (NASDAQ: SGRY) reported its second-quarter 2026 results on August 10, 2026. The company posted quarterly revenue of $848.9 million, a modest 2.7% year-over-year rise, aided by a 5.0% increase in same-facility revenues and a 4.8% uptick in revenue per case. The company logged a net loss of $15.0 million for the quarter, while Adjusted EBITDA stood at $125.2 million. Year-to-date revenue reached $1,659.8 million with YTD Adjusted EBITDA of $227.5 million.
Quarterly metrics in focus
- Revenue: $848.9 million for Q2 2026, up 2.7% YoY
- Same-facility revenue: +5.0% in Q2 2026
- Revenue per case: +4.8% (quarterly)
- Same-facility cases: +0.3% (quarterly)
- Net loss attributable to Surgery Partners, Inc.: $15.0 million (Q2 2026)
- Adjusted EBITDA: $125.2 million (Q2 2026)
- Liquidity: cash and cash equivalents $216.7 million; revolver capacity $617.8 million as of June 30, 2026
- Debt-to-EBITDA: approximately 4.4x at end of Q2 2026
Guidance and strategic arc
The company reaffirmed its full-year 2026 revenue forecast in the range of $3.35 billion to $3.45 billion and reiterated an Adjusted EBITDA target of at least $530 million, excluding a recently disclosed pending divestiture. Management underscored ongoing execution on its strategic priorities to support a return to growth, with particular emphasis on portfolio optimization and operational efficiency.
A notable development is the pending Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals. The company frames this as a driver of improved financial position through enhanced cash conversion and deleveraging, suggesting potential acceleration of deleveraging post-close.
Management tone and risk signals
In a tone typical of steady operators, executives Eric Evans (CEO) and Dave Doherty (CFO) highlighted disciplined execution and a focus on long-term value creation. The commentary positions the current quarter as a bridge to the company’s longer-term growth thesis, supported by industry tailwinds in the ASC (ambulatory surgery center) market and ongoing capital discipline.
From a disclosure perspective, the release does not provide a GAAP or non-GAAP EPS figure, which leaves EPS consensus and potential earnings surprise readings to investors and sell-side models. The net loss suggests a negative GAAP EPS for the quarter, but without an explicit per-share figure, analysts must rely on standard models to interpret the impact.
Implications for peers and the sector
The reported results reinforce a backdrop where mid-sized hospital- and ASC-focused operators are balancing modest revenue growth with meaningful leverage. A debt-to-EBITDA ratio around 4.4x keeps Surgery Partners in a range where refinancing risk and covenant considerations matter, especially if market liquidity tightens as investors price in transitional assets like Idaho Falls.
For peers, the Idaho Falls path could serve as a case study in portfolio optimization: divestitures may unlock capital for deleveraging or capex that improves efficiency metrics. Investors will watch how the pending transaction affects EBITDA quality and the sustainability of revenue growth as the company upgrades operations and negotiates with payors and physicians on cost structures.
Outlook: what to watch next
The key near-term question is how the revenue trajectory evolves as the company holds steady on its revenue forecast while pursuing portfolio changes. If the Idaho Falls deal closes and debt comes down meaningfully, the stock could reprice on leverage relief alone, even before any meaningful uptick in same-facility volumes materializes. If the market senses that the earnings trajectory remains constrained by cost structures or payer dynamics, the EPS profile could remain under pressure despite steady revenue growth.
In sum, SGRY looks more like a company executing a plan than one chasing a narrative. The question for investors and sector peers is whether this plan is sufficient to convert modest top-line momentum into durable profitability, or if the next chapter hinges on the timing and impact of divestitures, debt management, and the pace of ASC-market expansion.